Company registration number 12845735 (England and Wales)
ALPHA BIOLABORATORIES COVID-19 TESTING
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PAGES FOR FILING WITH REGISTRAR
ALPHA BIOLABORATORIES COVID-19 TESTING
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 3
ALPHA BIOLABORATORIES COVID-19 TESTING
BALANCE SHEET
AS AT 31 MARCH 2025
31 March 2025
- 1 -
2025
2024
Notes
£
£
£
£
Current assets
Debtors
3
191
880,761
Creditors: amounts falling due within one year
4
-
0
(182,483)
Net current assets
191
698,278
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
91
698,178
Total equity
191
698,278

For the financial year ended 31 March 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 22 December 2025 and are signed on its behalf by:
Mr D Thomas
Director
Company registration number 12845735 (England and Wales)
ALPHA BIOLABORATORIES COVID-19 TESTING
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
1
Accounting policies
Company information

Alpha Biolaboratories Covid-19 Testing is a private company limited by shares incorporated in England and Wales. The registered office and principal place of business is 14 Webster Court, Carina Park, Westbrook, Warrington, United Kingdom, WA5 8WD.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Prior period error

During the year, errors were identified in the recording of intercompany balances arising from incorrect postings in prior accounting periods. These errors resulted in certain intercompany debtor and creditor balances being misstated.

 

The directors have determined that it is impracticable to quantify the impact of these errors on individual prior periods due to incomplete historical accounting records and the inability to reliably reconstruct the original transactions without the use of hindsight.

 

Accordingly, in line with Section 10 of FRS 102, the errors have been corrected in the current year by an adjustment to opening retained earnings. Comparative information has not been restated.

 

The total adjustment recognised in opening retained earnings as at 01 April 2024 was £698,087 (decrease).

1.3
Financial instruments

Other debtors

Other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method unless the effect of discounting would be immaterial. In such cases, other debtors are stated at cost less impairment losses for bad and doubtful debts.

 

Other creditors

Other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method unless the effect of discounting would be immaterial, in which case they are stated at cost.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
0
0
ALPHA BIOLABORATORIES COVID-19 TESTING
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 3 -
3
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
191
880,761
4
Creditors: amounts falling due within one year
2025
2024
£
£
Other creditors
-
0
182,483
5
Related party transactions

The following amounts were outstanding at the reporting date:

2025
2024
Amounts due to related parties
£
£
Companies under common control
-
182,483
2025
2024
Amounts due from related parties
£
£
Companies under common control
-
880,421

Certain balances with related parties were corrected during the year following the identification of historical posting errors. These corrections were recognised through opening retained earnings, as detailed in note 1.2.

6
Ultimate Controlling Company

The ultimate controlling party are the directors of the business by virtue of their controlling interest in the business.

2025-03-312024-04-01falsefalsetrue22 December 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityMs R ThomasMr D Thomas128457352024-04-012025-03-31128457352025-03-31128457352024-03-3112845735core:WithinOneYear2025-03-3112845735core:WithinOneYear2024-03-3112845735core:ShareCapital2025-03-3112845735core:ShareCapital2024-03-3112845735core:RetainedEarningsAccumulatedLosses2025-03-3112845735core:RetainedEarningsAccumulatedLosses2024-03-3112845735bus:Director22024-04-012025-03-31128457352023-04-012024-03-3112845735core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3112845735core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3112845735core:CurrentFinancialInstruments2025-03-3112845735core:CurrentFinancialInstruments2024-03-3112845735bus:EntityNoLongerTradingButTradedInPast2024-04-012025-03-3112845735bus:PrivateLimitedCompanyLtd2024-04-012025-03-3112845735bus:SmallCompaniesRegimeForAccounts2024-04-012025-03-3112845735bus:FRS1022024-04-012025-03-3112845735bus:AuditExemptWithAccountantsReport2024-04-012025-03-3112845735bus:Director12024-04-012025-03-3112845735bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP